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Policy coherencea b s t r a c t
Through its Global Action Plan for Influenza Vaccines (GAP), the World Health Organization (WHO) in col-
laboration with the United States Department of Health and Human Services has produced a checklist to
support policy-makers and influenza vaccine manufacturers in identifying key technological, political,
financial, and logistical issues affecting the sustainability of influenza vaccine production. This checklist
highlights actions in five key areas that are beneficial for establishing successful local vaccine manufac-
turing. These five areas comprise: (1) the policy environment and health-care systems; (2) surveillance
systems and influenza evidence; (3) product development and manufacturing; (4) product approval
and regulation; and (5) communication to support influenza vaccination. Incorporating the checklist into
national vaccine production programmes has identified the policy gaps and next steps for countries
involved in GAP’s Technology Transfer Initiative. Lessons learnt from country experiences provide context
and insight that complement the checklist’s goal of simplifying the complexities of influenza prevention,
preparedness, and vaccine manufacturing.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
The World Health Organization (WHO) Global Action Plan for
Influenza Vaccines (GAP) was developed in order to address chal-
lenges to sustainable influenza vaccine production and uptake in
developing countries. Its aim is to increase equitable access to pan-
demic vaccines while contributing to international pandemic pre-
paredness efforts. WHO directly supports 14 developing
countries to establish or expand influenza vaccine manufacturing.
This support is provided as part of a larger WHO mandate born
within the Global Strategy and Plan of Action on Public Health,
Innovation and Intellectual Property (GSPA-PHI) [1], approved in
2008 by Member States. Within the GSPA-PHI, the transfer of tech-
nology is a prominent feature to promote local production and
improve access to medicines, vaccines, and diagnostics in develop-
ing countries. Transfer of technology principles align closely withthe key components of sustainable local influenza vaccine
production.
Within GAP’s objectives, there is a focus on increasing seasonal
influenza vaccination coverage to stimulate global pandemic vac-
cine production capacity and to strengthen national regulatory
competencies. However, the multi-sectorial nature of influenza
vaccine manufacturing requires policy-makers and manufacturers
to address a mix of technological, political, financial, and logistical
issues that collectively affect sustainable production in developing
countries [2].
GAP objectives also favour sustainable local vaccine production.
Local vaccine production offers the following benefits [3]:
 better pandemic preparedness through development of local
sources of vaccines;
 a more reliable supply of medical products, reducing the likeli-
hood of distribution disruptions;
 more efficient supply chains in rural and poor areas and thus
improved distribution times;
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assuming the production scale is sufficiently large, are less
expensive;
 higher quality products, better suited to local culture and
conditions;
 stimulation of local innovation capacity and the development of
human capital;
 development of export capacity for products, improving the
national balance of payments; and
 increased employment generation and spill-over effects into
other sectors of the economy.
As shown in Fig. 1, health and industrial sectors can work
together, with government support, to establish policies that con-
tribute to their shared goals.
Local vaccine production and improved access to medical prod-
ucts can be stimulated by coordinated industrial, technology and
health policies. Prioritization of local production can galvanize
action targeting immediate barriers, such as lack of research and
development capacities, resources, and expertise, which will result
in broader impacts to the health, science, technology and industry
fields. Governments are encouraged to examine these potential
investments in light of the broader impact to other fields and as
an opportunity to foster and drive industry and innovation locally.
The return on investment must be substantial and sustainable for
manufacturers to partner.
Sustainability also requires a coherent policy environment, reli-
able government procurement, product quality assurance, and
market certainty. In addition to achieving public health objectives,
there are strong economic and political drivers to establish and
enhance national capacity to manufacture medical technologies.2. Components of an enabling environment for sustainable
local production of influenza vaccines
Over the last 10 years, through the implementation of GAP,
WHO has distilled expertise and experiences into a checklist
designed to support policy-makers and manufacturers in develop-
ing countries who are seeking to improve influenza vaccine sus-
tainability. This checklist addresses the following areas: (1) the
policy environment and health-care systems; (2) surveillance sys-
tems and influenza evidence; (3) product development and manu-
facturing; (4) product approval and regulation; and (5)
communication to support influenza vaccination.
The checklist identifies, for each of the five specified areas, con-
ditions that could increase the likelihood of sustainable local pro-
duction and the use of influenza vaccines. These conditions are
outlined below (see also Annex 1: Supplementary material).2.1. Policy environment and health-care systems
National stakeholders develop policies to achieve their health
objectives, based on recommendations developed by experts, such
as Strategic Advisory Group expert (SAGE) on immunization, GAVI
alliance, WHO, etc. International recommendations should be
adapted to local specificities, while maintaining the global and
inclusive approach to combat seasonal and pandemic influenza.
Local vaccine production and improved access to medical products
can be stimulated by coordinated industrial, technology and health
policies.2.1.1. Health system policies
Six key interconnected desirable components of health system
policies are listed below and represented visually in Fig. 2: Strong political will and buy-in are critical when establishing
influenza as a national and/or regional priority. Establishing
strong political will at leadership levels often results in
increased resources, high-level public political commitment,
cooperation to establish new policies or change existing
ones, and enablement to navigate complex regulatory
environments
 The use of international, regional, and national influenza recom-
mendations to inform local policy development.
 Coherence among relevant national health policies and pro-
grammes ensures synergies between new and existing
programmes.
 An established seasonal influenza vaccination programme can
mitigate the effects of pandemic influenza events leading to
stronger national security preparedness.
 A seasonal vaccination programme that leverages existing
health system infrastructure and human resources to expand
capacities in the routine health-care system.
 Inclusion of seasonal influenza vaccination in health insurance
schemes or direct provision by the public health sector [5].
2.1.2. Non-health system-based policies
In addition to health-focused policies, governments interested
in developing local sustainable vaccine production are advised to
coordinate relevant industrial, procurement, trade, and workforce
policies. Fig. 3 provides a graphic depiction of these additional rec-
ommended policy avenues, which include:
 Interministerial coordination and strategic vision for industrial,
health and economic development policies; this is crucial given
the multi-sectorial space in which influenza vaccine manufac-
turing takes place.
 Policies that supports the development of good manufacturing
practices. The policy environment should encourage scientific
and academic institutions to conduct laboratory research as
well as stimulate upstream and downstream research on bio-
logicals and biomanufacturing.
 Relevant national and regional procurement and distribution
policies to promote in-country production and sourcing of
materials, in accordance with international agreements with
third parties.
 Governments and manufacturers’ full awareness of the conse-
quences that multilateral and bilateral trade agreements have
on the economic and public health situation of the country with
respect to commercialisation, such as the impact of removal of
trade barriers for national manufacturers. The development of a
skilled local workforce, through governmental incentives and
education policies to prevent brain-drain, and partnerships
between manufacturers and academia.
2.2. Surveillance systems and influenza evidence
Within any health system, the surveillance system has a critical
role in providing relevant, accurate, and timely information for
decision- and policy-making. Fig. 4 depicts the flow of information
from the surveillance system and resulting data analysis to the
subsequent disease burden and cost-effectiveness research. These
results need to be framed within the larger political, economic,
and geographic context for policy-makers. Conditions that favour
effective evidence gathering include:
 A surveillance system that utilises all available resources, such
as sentinel sites, population-based studies, insurance data, hos-
pital and out-patient clinic, and regional data, to ensure regular
burden of disease data collection.
Fig. 1. Multisectoral partnerships can improve local vaccine production, UHC; Universal health coverage. Source: reference [4].
Fig. 2. Health system policies: key components.
Fig. 3. Beneficial non-health based policies.
Fig. 4. Data translation: from surveillance to policy.
1 Vaccine probe studies are randomised clinical trials used to understand the
burden of a certain disease and how vaccine use can potentially decrease this burden.
They can also be used to establish causation between a specific pathogen and disease
[6].
C. Nannei et al. / Vaccine 34 (2016) 5425–5429 5427 Clear definition of which data should be collected and which
information systems should be used to accurately and appropri-
ately analyse data that streamlines timely reporting to regional
and international databases and dissemination of results. Investment in local burden of disease and cost-effectiveness
studies to build evidence for influenza vaccination policies. If
possible, consider probe1 studies to evaluate the vaccine-
preventable burden of disease [6].
 Incorporation of morbidity and mortality data from neighbour-
ing areas and various available proxies to understand the
impact of seasonal influenza on the country population.
 Evidence generated by the data analysis should be framed by
larger economic and geopolitical considerations for decision-
makers, particularly in the context of global health security
and pandemic preparedness.
2.3. Product development and manufacturing
Countries implementing policies to initiate local influenza vac-
cine production must consider the pipeline and manufacturing
process. In this respect, the following would be considered
advantageous:
 A solid business plan that considers the production environ-
ment and the marketplace where the product will be sold and
used, the production costs and price of the product (which are
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other products produced in the facility, running costs, and
infrastructure costs), the initial investment, and the time to
market and regulatory pathway for the product.
 Reliable and stable supplies of utilities (e.g. water, electricity),
with a focus on developing mechanisms that encourage self-
sufficiency.
 Secure supply chain for all components, taking into account
their costs, their foreseeable substitution, and their
maintenance.
 Identification of available market niches to overcome con-
straints due to price of the product or size of the market.
 Strategies to mitigate business risks by considering seasonality,
possible underutilisation of human resources and infrastruc-
ture, and additional products manufactured in the facility.
 Government and industry policies and programmes to bolster
skilled workforce capacity and retention. Strong links and con-
tinuous dialogue with academic institutions support the avail-
ability of skills necessary to perform every step of the
production process and ensure high managerial competencies.
 Realistic business and marketing strategies to identify return on
investment, based on the potential size of the national, regional,
and international markets.
 Full adherence to good manufacturing practice (GMP) and qual-
ity control procedures to guarantee a smoother production pro-
cess and quality of the final product, thereby reducing the risk
of costs linked to substandard quality steps or by-products.
 Strategically plan and design clinical trials and identify relevant
partners for clinical trial administration. The product’s refer-
ence market is established by focusing on the target popula-
tions and reviewing the safety and effectiveness of the
product. This also helps to create competitive advantages with
the other manufacturers.
 Active engagement in advocacy associations and networks that
sustain influenza vaccine manufacturing helps to raise aware-
ness of issues faced by manufacturers in developing countries.
 Building in flexibility into various parts of the production pro-
cess, including the sourcing of materials, increases pandemic
preparedness. Also, the chosen technologies affect pandemic
response time and the ramp-up capacity.
2.4. Product approval and regulation
In terms of creating an enabling regulatory environment for
local influenza vaccine production the following considerations
merit attention:
 The national regulatory authority (NRA) should be able to
assess, license, control quality, and conduct surveillance of bio-
logical medical products. For countries producing vaccines, the
NRA should be able to exercise the six recommended control
functions2 in a competent and independent manner, backed up
with enforcement.
 If the previous condition is met, the national manufacturer can
aspire to meet WHO’s recommendation for United Nations pre-
qualification of its product for better viability in local and inter-
national markets.
 With the emerging global market and the increasing number of
novel products, the volume of biological medicinal products
crossing national borders continues to rise. Participation in2 License of manufacturers and product regulation; surveillance of vaccine field
performance (post-marketing surveillance); system of lot release; laboratory access
(use of laboratory when needed); regular inspections for GMP; clinical trial approval
(evaluation of clinical performance).regional harmonisation efforts and integration of regulatory
approvals plays a key role in facilitating the accuracy of regula-
tory work and international capacity building efforts.
2.5. Communication to support influenza vaccination
An effective national communication system comprises:
 A communication policy, plan, and strategy to support the
development and implementation of influenza vaccination
policies.
 Communication research, monitoring, and evaluation of objec-
tives and agreed public health goals.
 Partnerships, stakeholders, and public engagement to imple-
ment the strategic objectives.
 Communication capacity building and training for all actors and
stakeholders involved in influenza programmes.
 Knowledge translation and information communication tech-
nologies (ICTs) that support efficiency and effectiveness of the
system and align them with the needs of 21st century informa-
tion society.
3. Lessons learnt from the application of the checklist to
national contexts
Over the last 4 years, WHO has conducted a series of assess-
ments in developing countries3 to analyse national policy environ-
ments in which influenza vaccine manufacturing occurs. Through
these experiences, several critical lessons and common findings have
emerged that can be useful for other countries pursuing sustainable
production and long-term availability of influenza vaccines. In par-
ticular, political awareness, financial accessibility of vaccination for
targeted populations, and a strong NRA have been shown to provide
a solid foundation for a coherent political and administrative
environment.
The first notable lesson is the need for strong political support
and government investment to develop a local product. After the
2009 influenza A (H1N1) pandemic, countries realised that they
were ill-prepared and that national systems were too weak to pro-
tect their population. State involvement and support can take sev-
eral forms: the development and updating of a pandemic influenza
preparedness plan, financial commitment, and long-term supply
agreements with manufacturers.
A second lesson learnt from countries’ experiences relates to
access to health care. Studies show that a high rate of vaccination
occurs when there is public or third-party reimbursement of vacci-
nation, through government run health-care centres or insurance
schemes [5,7,8]. When vaccinations are financially accessible to
target populations, coverage rates increase substantially.
The existence of a strong NRA, operating in accordance with
international and WHO standards, offers a strong support to the
manufacturer during the product development and testing process.
This regulatory presence also helps build confidence among the
population that the vaccine is safe, effective, and of high quality.
The NRA provides further assurance that the product will reach
the population under reliable supply conditions, and the product
will be monitored for safety throughout its lifespan.
Countries and manufacturers receiving technology for influenza
vaccine production require skills and staff that are trained appro-
priately. From the manufacturers’ side, workers need to be trained
to use the technology, and in parallel, awareness should be raised
among regulators, administrative staff, surveillance system staff,3 The exercise has been applied in seven countries: Brazil, Indonesia, Mexico,
Morocco, South Africa, Thailand, and Viet Nam.
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able, it is correctly administered. To this end, major investments
in communication and training, especially of health-care workers,
are paramount to ensure high levels of vaccination among at-risk
populations [9].
Despite ample evidence of the disease burden imposed by influ-
enza [10,11] some countries have yet to conduct their own analy-
ses of the socioeconomic impact of influenza. Strong evidence of
the burden of disease will increase the understanding of the impact
of the seasonal influenza virus and comorbidities and help target
at-risk populations. Countries with well-developed surveillance
systems in place are able to make informed decisions about the
scale-up of influenza vaccine use. Probe studies are still underuti-
lised, but could estimate the vaccine preventable disease incidence
(VPDI)4 and establish causality of the disease [6].
WHO and countries developing influenza vaccine manufactur-
ing and production capacity that have incorporated the checklist’s
recommended targets have reported considerable successes. The
use of the checklist has increased interagency communication
and strategic planning that benefit both the short- and long-term
viability of the influenza vaccine production.
4. Conclusion
The use of the checklist has proven useful in the identification
of policy gaps and opportunities for better coherence of policies,
as a tool for policy-makers and manufacturers to address the com-
plexities of influenza prevention and preparedness and vaccine
manufacturing. WHO country assessment reports include a com-
pendium of policy options to strengthen sustainability of local pro-
duction and use of influenza vaccines. These reports will be
developed as a reference for countries willing to invest in influenza
preparedness through local production, and will be adapted to the
local context. By incorporating this checklist into a national vaccine
production programmes, countries can cultivate comprehensive
platforms for broader pandemic preparedness.
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